J. Mcainsh

发表

Atenolol and ischaemic heart disease: an overview.

J. Cruickshank, J. Mcainsh, 1991, Current medical research and opinion.

Pharmacokinetics of epanolol in elderly patients with stable angina pectoris.

I. Cockshott, J McAinsh, I D Cockshott, 1990, Arzneimittel-Forschung.

Studies on the pharmacokinetics and pharmacodynamics of atenolol in man

R. Ruffin, J. Mcainsh, J. Fitzgerald, 1978, European Journal of Clinical Pharmacology.

Human pharmacokinetic and pharmacodynamic studies on the atenolo (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug.

W. T. Simpson, J. Mcainsh, J. Fitzgerald, 1976, British journal of clinical pharmacology.

Percutaneous absorption of chlorhexidine in neonatal cord care.

P. Aggett, J. Mcainsh, L. Cooper, 1981, Archives of disease in childhood.

Absorption of chlorhexidine from the intact skin of newborn infants.

J. Mcainsh, S. Ellis, J. Cowen, 1979, Archives of disease in childhood.

Bioavailability of sustained release propranolol formulations.

N. Baber, J. Young, J. Mcainsh, 1981, Biopharmaceutics & drug disposition.

“Chlorhexidine: Attempts to Detect Percutaneous Absorption in Man”

A. Rushton, J. Mcainsh, D. Case, 1976 .

Beta-adrenoceptor blockers and the blood-brian barrier.

J. Bartlett, J. Cruickshank, G. Neil-Dwyer, 1981, British journal of clinical pharmacology.

Melt rheology of the polyether from bisphenol-a and 4,4'-dichlorodiphenylsulfone

N. J. Mills, J. Mcainsh, A. Nevin, 1970 .

BETA BLOCKERS AND QUALITY OF LIFE

J. Mcainsh, J. Cruikshank, 1992, The British journal of clinical practice.

A study of the pharmacokinetics and pharmacodynamics of nifedipine in combination with atenolol

H. Adam, J. Mcainsh, J. Ryan, 1991, Biopharmaceutics & drug disposition.

Dilute solution properties of the polyether from bisphenol ‘A’ and 4,4′ dichlorodiphenyl sulphone

G. Allen, J. Mcainsh, C. Strazielle, 1969 .

The unperturbed dimensions of polysulphone a in dimethylformamide

G. Allen, J. Mcainsh, 1970 .

Clinical pharmacologic observations on atenolol, a beta‐adrenoceptor blocker

R. Shanks, D. McDevitt, J. Kelly, 1976, Clinical pharmacology and therapeutics.

Beta-blockers and central nervous system side effects.

J. Cruickshank, J. Mcainsh, 1990, Pharmacology & therapeutics.

Relaxation phenomena in some aromatic polymers: effect of water content on the low temperature relaxation

G. Allen, J. Mcainsh, G. Jeffs, 1971 .

beta-Adrenoreceptor-blocking agents and the blood-brain barrier.

G Neil-Dwyer, J. Cruickshank, G. Neil-Dwyer, 1980, Clinical science.

β-Blockers and Renal Function

D. Waller, D. Warren, J. Mcainsh, 1983, Drugs.

Atenolol kinetics in renal failure

D. Warren, J. Mcainsh, S. Smith, 1980, Clinical pharmacology and therapeutics.

Metabolism of atenolol in man.

P. Reeves, J. Mcainsh, M. Winrow, 1978, Xenobiotica; the fate of foreign compounds in biological systems.

Pharmacokinetics of atenolol in patients with renal impairment

P. Zech, N. Pozet, J. Sassard, 1977, European Journal of Clinical Pharmacology.

Response to atenolol in arterial hypertension in relation to renal function, pharmacokinetics and renin activity.

M. Labeeuw, P. Zech, N. Pozet, 1977, Postgraduate medical journal.

Levels of the beta-blockers atenolol and propranolol in the breast milk of women treated for hypertension in pregnancy.

K. Thorley, J. Mcainsh, 1983, Biopharmaceutics & drug disposition.

Atenolol in the treatment of pregnancy-induced hypertension.

J. Cruickshank, K. Thorley, J. Mcainsh, 1981, British journal of clinical pharmacology.

Pharmacokinetics of atenolol in hypertensive subjects with and without co-administration of chlorthalidone

R. Sega, G. Tognoni, E. Riva, 1980, European Journal of Clinical Pharmacology.

Pharmacokinetic and pharmacodynamic studies with long-acting propranolol.

N. Baber, Young, J. Young, 1978, British journal of clinical pharmacology.

Theoretical Michaelis — Menten elimination model for propranolol

J. Mcainsh, M. Gay, 1985, European Journal of Drug Metabolism and Pharmacokinetics.

/3-ADRENOCEPTOR BLOCKERS AND THE BLOOD-BRAIN BARRIER

J. Cruickshank, J. Mcainsh, '. GLENNNEIL-DWYER, 2006 .

The use of long-acting propranolol (‘Inderal’ LA) in the management of elderly hypertensive patients

J. Mcainsh, D. Tovey, C. Hamdy, 2004, European Journal of Clinical Pharmacology.

Long-Acting Propranolol in the Prophylaxis of Migraine: A Comparative Study of Two Doses

N. Cleave, J. Mcainsh, P. Savundra, 1990, Cephalalgia : an international journal of headache.

A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls.

R. Shanks, J. Hayes, R. Watson, 1987, British journal of clinical pharmacology.

Comparative pharmacological and pharmacokinetic observations on propranolol (long acting formulation) and bendrofluazide administered separately and concurrently to volunteers.

R. Shanks, W. Castle, D. Harron, 1982, British journal of clinical pharmacology.

Bioavailability of propranolol and bendrofluazide formulations.

N. Baber, J. Young, J. Mcainsh, 1981, Biopharmaceutics & drug disposition.

The effect of food on the in vivo release of propranolol from a PVC matrix tablet in the dog

J. Mcainsh, R. Grundy, D. C. Taylor, 1974, The Journal of pharmacy and pharmacology.

LOW-DOSE ORAL PROPRANOLOL

N. Baber, J. Mcainsh, 1978, The Lancet.

Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.

D. Bateman, A. Salahudeen, J. Mcainsh, 1984, British journal of clinical pharmacology.

Relationship between blood level of atenolol and pharmacologic effect

A. Amery, P. Lijnen, T. Reybrouck, 1977, Clinical pharmacology and therapeutics.

Clinical pharmacokinetics of atenolol.

J. Mcainsh, 1977, Postgraduate medical journal.

Tissue atenolol levels following chronic β‐adrenoceptor blockade using oral atenolol in dogs

J. Mcainsh, M. Davies, 1986, The Journal of pharmacy and pharmacology.

Pharmacokinetic studies with atenolol in the dog

J. Mcainsh, B. Holmes, 1983, Biopharmaceutics & drug disposition.

Bioavailability in man of atenolol and chlorthalidone from a combination formulation.

B. Holmes, J. Young, J. Mcainsh, 1981, Biopharmaceutics & drug disposition.

Bioavailability of atenolol formulations

J. Mcainsh, Jean Young, James McAinsh, 1980, Biopharmaceutics & drug disposition.

Pharmacokinetic and pharmacodynamic studies in man with an antianginal agent 'Visacor'.

I. Cockshott, J. Mcainsh, S. Norris, 1990, Biopharmaceutics & drug disposition.